Photo: Twitter
').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();
Topics
Piramal | Piramal Enterprises | Stock Market
Photo: Twitter
').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();
Shares of Piramal Pharma closed at Rs 192 on Wednesday during their listing debut.
The company, which got listed separately following its demerger from Piramal Enterprises, was valued at Rs 22,882 crore at last close.
In FY22, the contract development and manufacturing (CDMO) vertical accounted for 59 per cent of its sales, complex hospital generics (CHG), 30 per cent and India consumer products business, 11 per cent.
Domestic brokerage Motilal Oswal has set a price target of Rs 210 for the stock.
“Using sum of the parts (SOTP), we value the CDMO business, CHG, and the ICH business based on 16x, 12x, and 18x FY24E EV/EBITDA respectively. We value Allergan JV (49 per cent stake) based on 18x FY24E PE,” it says.
Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!
First Published: Wed, October 19 2022. 18:09 IST
JPMorgan has deployed an AI-based research analyst chatbot to enhance productivity among its workforce, with approximate... Read more
Private equity has emerged as a significant force in the global financial landscape, driving substantial growth and inve... Read more
The world’s leading financial stability watchdog has issued a warning about the unresolved vulnerabilities within the ... Read more
In a week marked by strong financial performance, JPMorgan Chase & Co. reported a 25% rise in profits, and US small-... Read more
The financial industry is a competitive landscape where big banks and regional banks vie for market share. Each type of ... Read more
The landscape of philanthropic advisory services provided by private banks has undergone a significant transformation. T... Read more